Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
Did you mean: (tetrabenazine)?
80 results
  • Tardive Dyskinesia: Treatment Update. [Review]
    Curr Neurol Neurosci Rep 2019; 19(9):69Arya D, Khan T, … Fernandez HH
  • Tardive dyskinesia (TD) is caused by exposure to medications with dopamine antagonism, mainly antipsychotics. It often distresses individuals, physically and emotionally and affects their quality of life. We evaluated peer-reviewed recently published articles with a goal of providing a critically appraised update on the latest advancements in this field.
  • Tardive Syndromes. [Journal Article]
    Continuum (Minneap Minn) 2019; 25(4):1081-1098Friedman JH
  • CONCLUSIONS: Tardive syndromes remain a public health risk. Second-generation antipsychotics have not been proven to have less risk than first-generation drugs in causing tardive syndromes and are nevertheless being used more widely to treat depression, bipolar disease, and insomnia. Symptomatic treatment for tardive syndromes is available, although expensive.
  • Tics and Tourette Syndrome. [Journal Article]
    Continuum (Minneap Minn) 2019; 25(4):936-958Singer HS
  • CONCLUSIONS: Tics, defined as sudden, rapid, recurrent, nonrhythmic motor movements or vocalizations, are essential components of Tourette syndrome. Although some tics may be mild, others can cause significant psychosocial, physical, and functional difficulties that affect daily activities. In addition to tics, most affected individuals have coexisting neuropsychological difficulties (attention deficit hyperactivity disorder, obsessive-compulsive disorder, anxiety, mood disorder, disruptive behaviors, schizotypal traits, suicidal behavior, personality disorder, antisocial activities, and sleep disorders) that can further impact social and academic activities or employment.
  • Recent developments in drug-induced movement disorders: a mixed picture. [Review]
    Lancet Neurol 2019; 18(9):880-890Factor SA, Burkhard PR, … Comella CL
  • A large and ever-growing number of medications can induce various movement disorders. Drug-induced movement disorders are disabling but are often under-recognised and inappropriately managed. In particular, second generation antipsychotics, like first generation agents, are associated with potentially debilitating side-effects, most notably tardive syndromes and parkinsonism, as well as potential…
  • A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine. [Review]
    Ther Adv Psychopharmacol 2019; 9:2045125319847882Patel RS, Mansuri Z, … Zafar MK
  • Recent reports state that the prevalence of tardive dyskinesia (TD) is 32% with typical antipsychotics, and 13% with atypical antipsychotics. Current evidence-based recommendations determine an unmet need for efficacious treatment of TD. This systematic review was planned to update the evidence for TD treatment, comparing two vesicular monoamine transporter 2 (VMAT2) inhibitors, deutetrabenazine …
  • Medical Genetics Summaries: Deutetrabenazine Therapy and CYP2D6 Genotype [BOOK]
    National Center for Biotechnology Information (US): Bethesda (MD)Pratt V, McLeod H, … Malheiro ADean LBOOK
  • Deutetrabenazine (brand name Austedo) is used to treat chorea associated with Huntington disease (HD) and tardive dyskinesia (TD). Both HD and TD are types of involuntary movement disorders. The recommended starting dose is 6 mg once daily for individuals with HD and 12 mg per day (6 mg twice daily) for individuals with TD. The maximum recommended daily dosage for both conditions is 48 mg (24 mg,…
  • Tardive Dyskinesia: New Treatments Available. [Journal Article]
    J Psychosoc Nurs Ment Health Serv 2019; 57(5):11-14Limandri BJ
  • Tardive dyskinesia (TD), the choreoathetoid movements of fingers, arms, legs, and trunk and irregular stereotypical movements of the mouth, face, and tongue, has been the scourge of antipsychotic medications since the approval of chlorpromazine. TD tends to occur late in treatment and sometimes remains after discontinuation of the antipsychotic medication. With the recent approval of two medicati…
New Search Next